Shitao Rao1, Xinyu Han2, Mai Shi3, Cynthia O Siu4, Mary Miu Yee Waye5, Guangming Liu6, Yun Kwok Wing7. 1. Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, N.T., Hong Kong, SAR, China; The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, N.T., Hong Kong, SAR, China. 2. The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, N.T., Hong Kong, SAR, China; College of Food and Biological Engineering, Jimei University, Xiamen, Fujian, China. 3. School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, N.T., Hong Kong, SAR, China. 4. COS & Associates Ltd., Central District, Hong Kong, SAR, China. 5. The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, N.T., Hong Kong, SAR, China. 6. College of Food and Biological Engineering, Jimei University, Xiamen, Fujian, China. Electronic address: gmliu@jmu.edu.cn. 7. Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, N.T., Hong Kong, SAR, China. Electronic address: ykwing@cuhk.edu.hk.
Abstract
BACKGROUND: Associations of the serotonin transporter promoter polymorphism (5-HTTLPR) with bipolar disorder (BPD) and treatment response in bipolar patients were not conclusive. This study not only assessed the association between the 5-HTTLPR and BPD with accumulating relevant studies, but also in the first time evaluated the effect of the 5-HTTLPR on both anti-depressive and anti-manic treatment responses in bipolar patients. METHODS: PubMed, Embase, PsycINFO, Cochrane Library and Cochrane Control Trials databases were systematically searched before February 2017. This meta-analysis followed the PRISMA guidelines. RESULTS: A total of 32 population-based studies (5567 cases and 6993 controls) and 9 family-based studies (837 trios) were finally screened out and statistically joined into a single meta-analysis that revealed an association between S allele and an increased risk of BPD (OR = 1.06, p = .038). Pooled analysis of the 32 population-based studies indicated an association of S-carrier genotypes with an increased risk of BPD (OR = 1.10, p = .029). Meanwhile, the association remained significant in Caucasians (OR = 1.15, p = .004), which could provide an enough power (88%) to detect a significant association. Regarding the treatment response studies, 6 studies reporting the relationship of the 5-HTTLPR in anti-depressive remission rate (1034 patients) and 7 studies reporting in response rate (1098 patients) were included for pooled analyses. We observed a significant association of S-carrier genotypes with a reduced anti-depressive remission rate (OR = 0.64, p = .006) but not with anti-depressive response rate. The association between the 5-HTTLPR with anti-manic response rate was not observed in the included 6 studies (676 patients). CONCLUSIONS: The present study supported the presence of a marginal but detectable effect of the 5-HTTLPR on susceptibility to BPD. Moreover, the detected association in Caucasian was statistically reliable. Besides, the 5-HTTLPR was identified as a useful predictor for anti-depressive remission but not for anti-depressive or anti-manic response.
BACKGROUND: Associations of the serotonin transporter promoter polymorphism (5-HTTLPR) with bipolar disorder (BPD) and treatment response in bipolarpatients were not conclusive. This study not only assessed the association between the 5-HTTLPR and BPD with accumulating relevant studies, but also in the first time evaluated the effect of the 5-HTTLPR on both anti-depressive and anti-manic treatment responses in bipolarpatients. METHODS: PubMed, Embase, PsycINFO, Cochrane Library and Cochrane Control Trials databases were systematically searched before February 2017. This meta-analysis followed the PRISMA guidelines. RESULTS: A total of 32 population-based studies (5567 cases and 6993 controls) and 9 family-based studies (837 trios) were finally screened out and statistically joined into a single meta-analysis that revealed an association between S allele and an increased risk of BPD (OR = 1.06, p = .038). Pooled analysis of the 32 population-based studies indicated an association of S-carrier genotypes with an increased risk of BPD (OR = 1.10, p = .029). Meanwhile, the association remained significant in Caucasians (OR = 1.15, p = .004), which could provide an enough power (88%) to detect a significant association. Regarding the treatment response studies, 6 studies reporting the relationship of the 5-HTTLPR in anti-depressive remission rate (1034 patients) and 7 studies reporting in response rate (1098 patients) were included for pooled analyses. We observed a significant association of S-carrier genotypes with a reduced anti-depressive remission rate (OR = 0.64, p = .006) but not with anti-depressive response rate. The association between the 5-HTTLPR with anti-manic response rate was not observed in the included 6 studies (676 patients). CONCLUSIONS: The present study supported the presence of a marginal but detectable effect of the 5-HTTLPR on susceptibility to BPD. Moreover, the detected association in Caucasian was statistically reliable. Besides, the 5-HTTLPR was identified as a useful predictor for anti-depressive remission but not for anti-depressive or anti-manic response.
Authors: Alfredo B Cuéllar-Barboza; Susan L McElroy; Marin Veldic; Balwinder Singh; Simon Kung; Francisco Romo-Nava; Nicolas A Nunez; Alejandra Cabello-Arreola; Brandon J Coombes; Miguel Prieto; Hannah K Betcher; Katherine M Moore; Stacey J Winham; Joanna M Biernacka; Mark A Frye Journal: Int J Bipolar Disord Date: 2020-07-04
Authors: Muhammad Imran Qadeer; Ali Amar; Yung-Yu Huang; Eli Min; Hanga Galfalvy; Shahida Hasnain; J John Mann Journal: Sci Rep Date: 2021-01-18 Impact factor: 4.379
Authors: Andrea Boscutti; Alessandro Pigoni; Giuseppe Delvecchio; Matteo Lazzaretti; Gian Mario Mandolini; Paolo Girardi; Adele Ferro; Michela Sala; Vera Abbiati; Marco Cappucciati; Marcella Bellani; Cinzia Perlini; Maria Gloria Rossetti; Matteo Balestrieri; Giuseppe Damante; Carolina Bonivento; Roberta Rossi; Livio Finos; Alessandro Serretti; Paolo Brambilla Journal: Genes (Basel) Date: 2022-03-09 Impact factor: 4.096